Bordetella pertussis proteins dominating the major histocompatibility complex class II-presented epitope repertoire in human monocyte-derived dendritic cells

Clinical and Vaccine Immunology

Volumn 21, Issue 5, 2014, Pages 641-650

  Stenger, Rachel M ^a   Meiring, Hugo D ^b   Kuipers, Betsy ^a   Poelen, Martien ^a   Van Gaans van Den Brink, Jacqueline A M ^a   Boog, Claire J P ^b   De Jong, Ad P J M ^b   Van Els, Cécile A C M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b Institute for Translational Vaccinology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLOSUCCINATE SYNTHASE; BACTERIAL PROTEIN; BORDETELLA PERTUSSIS PROTEIN; CHAPERONIN; CYTOKINE; EARLY PREGNANCY FACTOR; ENVELOPE PROTEIN; EPITOPE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 13; INTERLEUKIN 5; LIPOPROTEIN; PEPTIDOGLYCAN; PERIPLASMIC PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRULENCE FACTOR; BACTERIAL ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL STRAIN; BORDETELLA PERTUSSIS; CD4+ T LYMPHOCYTE; DENDRITIC CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOBLOTTING; IMMUNOGENICITY; LYMPHOPROLIFERATIVE DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TH2 CELL; ADOLESCENT; ADULT; AGED; CELL PROLIFERATION; CHILD; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; SECRETION (PROCESS); YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BORDETELLA PERTUSSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHILD; CYTOKINES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNODOMINANT EPITOPES; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84899712492     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00665-13     Document Type: Article

References (71)

1. Cohen HH. 1963. Development of pertussis vaccine production and control in the National Institute of Public Health in the Netherlands during the years 1850-1962. Antonie Van Leeuwenhoek 29:183-201. http://dx.doi.org/10.1007/ BF02046052.
2. Hewlett EL, EdwardsKM. 2005. Clinical practice. Pertussis-not just for kids. N. Engl. J. Med. 352:1215-1222. http://dx.doi.org/10.1056/NEJMcp041025.
3. De Serres G, Boulianne N, Douville FM, Duval B. 1995. Pertussis in Quebec: ongoing epidemic since the late 1980s. Can. Commun. Dis. Rep. 21:45-48.
4. de Melker HE, Conyn-van Spaendonck MA, Rumke HC, van Wijngaarden JK, Mooi FR, Schellekens JF. 1997. Pertussis in the Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg. Infect. Dis. 3:175-178. http://dx.doi.org/10.3201/eid0302.970211. (Pubitemid 127431675)
5. Bass JW, Wittler RR. 1994. Return of epidemic pertussis in the United States. Pediatr. Infect. Dis. J. 13:343-345. http://dx.doi.org/10.1097/00006454- 199405000-00002. (Pubitemid 24145675)
6. Andrews R, Herceg A, Roberts C. 1997. Pertussis notifications in Australia, 1991 to 1997. Commun. Dis. Intell. 21:145-148.
7. Guris D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finck E, Wharton M, Livengood JR. 1999. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin. Infect. Dis. 28:1230-1237. http://dx.doi.org/10.1086/514776. (Pubitemid 29272795)
8. Gzyl A, Augustynowicz E, Rabczenko D, Gniadek G, Slusarczyk J. 2004. Pertussis in Poland. Int. J. Epidemiol. 33:358-365. http://dx.doi.org/10.1093/ ije/dyh012. (Pubitemid 38578836)
9. Centres for Disease Control and Prevention. 2013. Notifiable diseases and mortality tables. MMWR Morb. Mortal. Wkly. Rep. 61:719-732.
10. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. 2005. Duration of immunity against pertussis after natural infection or vaccination. Pediatr. Infect. Dis. J. 24: S58 -S61. http://dx.doi.org/10.1097/01.inf.0000160914.59160. 41.
11. He Q, Mertsola J. 2008. Factors contributing to pertussis resurgence. Future. Microbiol. 3:329-339. http://dx.doi.org/10.2217/17460913.3.3.329. (Pubitemid 352003143)
12. Crowcroft NS, Pebody RG. 2006. Recent developments in pertussis. Lancet 367:1926-1936. http://dx.doi.org/10.1016/S0140-6736(06)68848-X. (Pubitemid 43831996)
13. Berbers GA, de Greeff SC, Mooi FR. 2009. Improving pertussis vaccination. Hum. Vaccin. 5:497-503.
14. Cherry JD, Gornbein J, Heininger U, Stehr K. 1998. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16:1901-1906. http://dx.doi.org/10.1016/S0264-410X(98)00226-6. (Pubitemid 28473933)
15. Storsaeter J, Hallander HO, Gustafsson L, Olin P. 1998. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16:1907-1916. http://dx.doi.org/10.1016/S0264- 410X(98)00227-8. (Pubitemid 28473934)
16. Cherry JD. 2007. Immunity to pertussis. Clin. Infect. Dis. 44:1278-1279. http://dx.doi.org/10.1086/514350. (Pubitemid 46717288)
17. Olin P, Hallander HO, Gustafsson L, Reizenstein E, Storsaeter J. 2001. How to make sense of pertussis immunogenicity data. Clin. Infect. Dis. 33(Suppl 4):S288-S291. http://dx.doi.org/10.1086/322564. (Pubitemid 33152372)
18. Mills KH. 2001. Immunity to Bordetella pertussis. Microbes Infect. 3:655-677. http://dx.doi.org/10.1016/S1286-4579(01)01421-6. (Pubitemid 32607761)
19. Andreasen C, Powell DA, Carbonetti NH. 2009. Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS One 4:e7079. http://dx.doi.org/10.1371/journal.pone.0007079.
20. Ausiello CM, Lande R, Stefanelli P, Fazio C, Fedele G, Palazzo R, Urbani F, Mastrantonio P. 2003. T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice. Clin. Diagn. Lab. Immunol. 10:637-642. http://dx.doi.org/10.1128/CDLI.10.4.637-642.2003. (Pubitemid 36890449)
21. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. 2006. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J. Immunol. 177:7980-7989. (Pubitemid 44846315)
22. (+) T cells for key functions other than specific antibody production. J. Exp. Med. 191:1841-1852. http://dx.doi.org/10.1084/jem.191.11.1841.
23. Mills KH, Barnard A, Watkins J, Redhead K. 1993. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61:399-410. (Pubitemid 23030823)
24. Cahill ES, O'Hagan DT, Illum L, Barnard A, Mills KH, Redhead K. 1995. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 13:455-462. http://dx.doi.org/10.1016/0264-410X(94)00008-B.
25. van den Berg BM, David S, Beekhuizen H, Mooi FR, van Furth R. 2000. Protection and humoral immune responses against Bordetella pertussis infection in mice immunized with acellular or cellular pertussis immunogens. Vaccine 19:1118-1128. http://dx.doi.org/10.1016/S0264-410X(00)00329-7. (Pubitemid 32008277)
26. Vermeulen F, Verscheure V, Damis E, Vermeylen D, Leloux G, Dirix V, Locht C, Mascart F. 2009. Cellular immune responses of preterm infants after vaccination with whole cell or acellular pertussis vaccines. Clin. Vaccine Immunol. 17:258-262. http://dx.doi.org/10.1128/CVI.00328-09.
27. Dirix V, Verscheure V, Goetghebuer T, Hainaut M, Debrie AS, Locht C, Mascart F. 2009. Monocyte-derived interleukin-10 depresses the Bordetella pertussis-specific gamma interferon response in vaccinated infants. Clin. Vaccine Immunol. 16:1816-1821. http://dx.doi.org/10.1128/CVI.00314-09.
28. Guiso N, Njamkepo E, Vié le Sage F, Zepp F, Meyer CU, Abitbol V, Clyti N, Chevallier S. 2007. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 25:1390-1397. http://dx.doi.org/10.1016/j.vaccine.2006.10.048. (Pubitemid 46091822)
29. +T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin. Infect. Immun. 77: 896-903. http://dx.doi.org/10.1128/IAI.00769-08.
30. Ryan M, Murphy G, Gothefors L, Nilsson L, Storsaeter J, Mills KH. 1997. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J. Infect. Dis. 175: 1246-1250. http://dx.doi.org/10.1086/593682. (Pubitemid 27176522)
31. Ausiello CM, Lande R, la Sala A, Urbani F, Cassone A. 1998. Cell-mediated immuneresponse of healthy adults to Bordetella pertussis vaccine antigens. J. Infect. Dis. 178:466-470. http://dx.doi.org/10.1086/515628. (Pubitemid 28347930)
32. Mascart F, Verscheure V, Malfroot A, Hainaut M, Pierard D, Temerman S, Peltier A, Debrie AS, Levy J, Del Giudice G, Locht C. 2003. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J. Immunol. 170:1504-1509. (Pubitemid 36139521)
33. Mascart F, Hainaut M, Peltier A, Verscheure V, Levy J, Locht C. 2007. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 25:391-398. http://dx.doi.org/10.1016/j.vaccine.2006. 06.046. (Pubitemid 44873143)
34. Sallusto F, Lanzavecchia A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118. http: //dx.doi.org/10.1084/jem.179.4.1109.
35. De Magistris MT, Romano M, Bartoloni A, Rappuoli R, Tagliabue A.1989. Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map. J. Exp. Med. 169:1519-1532. http://dx.doi.org/10.1084/jem.169.5.1519. (Pubitemid 19126812)
36. Petersen JW, Holm A, Ibsen PH, Haslov K, Capiau C, Heron I. 1992. Identification of human T-cell epitopes on the S4 subunit of pertussis toxin. Infect. Immun. 60:3962-3970.
37. +T-cell clones against Bordetella pertussis. Infect. Immun. 59:3768-3773.
38. Meiring HD, Kuipers B, van Gaans-van den Brink JA, Poelen MC, Timmermans H, Baart G, Brugghe H, van Schie J, Boog CJ, de Jong AP, van Els CA. 2005. Mass tag-assisted identification of naturally processed HLA class II-presented meningococcal peptides recognized by CD4+T lymphocytes. J. Immunol. 174:5636-5643. (Pubitemid 40598087)
39. Hijnen M, van Gageldonk PG, Berbers GA, van Woerkom T, Mooi FR. 2005. The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr. Purif. 41:106-112. http://dx.doi.org/10.1016/j.pep.2005.01.014. (Pubitemid 40406369)
40. Robinson A, Gorringe AR, Funnell SG, Fernandez M. 1989. Serospecific protection of mice against intranasal infection with Bordetella pertussis. Vaccine 7:321-324. http://dx.doi.org/10.1016/0264-410X(89)90193-X. (Pubitemid 19215712)
41. Sekura RD, Fish F, Manclark CR, Meade B, Zhang YL. 1983. Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. J. Biol. Chem. 258:14647-14651.
42. Sato Y, Cowell JL, Sato H, Burstyn DG, Manclark CR. 1983. Separation and purification of the hemagglutinins from Bordetella pertussis. Infect. Immun. 41:313-320. (Pubitemid 13063056)
43. Poolman JT, Kuipers B, Vogel ML, Hamstra HJ, Nagel J. 1990. Description of a hybridoma bank towards Bordetella pertussis toxin and surface antigens.Microb.Pathog. 8:377-382.http://dx.doi.org/10.1016/0882-4010 (90)90024-K.
44. Hijnen M, de VR, Mooi FR, Schepp R, Moret EE, van Gageldonk P, Smits G, Berbers GA. 2007. The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition. Vaccine 25:5902-5914. http://dx.doi.org/10.1016/j.vaccine.2007.05.039.
45. Meiring HD, van der Heeft E, ten hove GJ, de Jong APJM. 2002. Nanoscale LC-MS(n): technical design and applications to peptide and protein analysis. J. separation science 25:557-568. http://dx.doi.org/10.1002/1615-9314(20020601)25:9 557::AID-JSSC557 3.0.CO;2-F.
46. Bian H, Reidhaar-Olson JF, Hammer J. 2003. The use of bioinformatics for identifying class II-restricted T-cell epitopes. Methods 29:299-309. http://dx.doi.org/10.1016/S1046-2023(02)00352-3. (Pubitemid 36513446)
47. Bian H, Hammer J. 2004. Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods 34:468-475. http://dx.doi.org/10.1016/j.ymeth. 2004.06.002. (Pubitemid 39469054)
48. Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, Holden MT, Churcher CM, Bentley SD, Mungall KL, Cerdeño-Tárraga AM, Temple L, James K, Harris B, Quail MA, Atkin R, Baker S, Basham D, Bason N, Cherevach I, Chillingworth T, Collins M, Cronin A, Davis P, Doggett J, Feltwell T, Goble A, Hamlin N, Hauser H, Holroyd S, Jagels K, Leather S, Moule S, Norberczak H, O'Neil S, Ormond D, Price C, Rabbinowitsch E, Rutter S, Sanders M, Saunders D, Seeger K, Sharp S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Unwin L, Whitehead S, Barrell BG, Maskell DJ. 2003. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat. Genet. 35:32-40. http://dx.doi.org/10.1038/ ng1227. (Pubitemid 37048593)
49. Godlewska R, Wisniewska K, Pietras Z, Jagusztyn-Krynicka EK. 2009. Peptidoglycan-associated lipoprotein (Pal) of Gram-negative bacteria: function, structure, role in pathogenesis and potential application in immunoprophylaxis. FEMS Microbiol. Lett. 298:1-11. http://dx.doi.org/10.1111/j.1574-6968.2009. 01659.x.
50. De Magistris MT, Romano M, Nuti S, Rappuoli R, Tagliabue A. 1988. Dissecting human T cell responses against Bordetella species. J. Exp. Med. 168:1351-1362. http://dx.doi.org/10.1084/jem.168.4.1351. (Pubitemid 18264870)
51. De Magistris MT, Di Tommaso A, Domenighini M, Censini S, Tagliabue A, Oksenberg JR, Steinman L, Judd AK, O'Sullivan D, Rappuoli R. 1992. Interaction of the pertussis toxin peptide containing residues 30-42 with DR1 and the T-cell receptors of 12 human T-cell clones. Proc. Natl. Acad. Sci. U. S. A. 89:2990-2994. http://dx.doi.org/10.1073/pnas.89.7.2990.
52. van de Waterbeemd B, Streefland M, Pennings J, van der Pol L, Beuvery C, Tramper J, Martens D. 2009. Gene-expression-based quality scores indicate optimal harvest point in Bordetella pertussis cultivation for vaccine production. Biotechnol. Bioeng. 103:900-908. http://dx.doi.org/10.1002/bit. 22326.
53. Watts C. 2012. The endosome-lysosome pathway and information generation in the immune system. Biochim. Biophys. Acta 1824:14-21. http://dx.doi.org/10. 1016/j.bbapap.2011.07.006.
54. Rammensee HG, Friede T, Stevanoviic S. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178-228. http://dx.doi.org/10.1007/ BF00172063.
55. Yarovinsky F, Kanzler H, Hieny S, Coffman RL, Sher A. 2006. Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell response. Immunity 25:655-664. http://dx.doi.org/10.1016/j.immuni.2006.07.015. (Pubitemid 44529033)
56. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR, Maitland M, Norgard MV, Plevy SE, Smale ST, Brennan PJ, Bloom BR, Godowski PJ, Modlin RL. 1999. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285:732-736. http://dx.doi.org/10.1126/ science.285.5428.732.
57. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, Zychlinsky A. 1999. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285: 736-739. http://dx.doi.org/10.1126/science.285.5428.736.
58. Hirschfeld M, Kirschning CJ, Schwandner R, Wesche H, Weis JH, Wooten RM, Weiss JJ. 1999. Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J. Immunol. 163:2382-2386. (Pubitemid 29399155)
59. Lee HK, Lee J, Tobias PS. 2002. Two lipoproteins extracted from Escherichia coli K-12 LCD25 lipopolysaccharide are the major components responsible for Toll-like receptor 2-mediated signaling. J. Immunol. 168: 4012-4017. (Pubitemid 34298406)
60. Liang MD, Bagchi A, Warren HS, Tehan MM, Trigilio JA, Beasley-Topliffe LK, Tesini BL, Lazzaroni JC, Fenton MJ, Hellman J. 2005. Bacterial peptidoglycan-associated lipoprotein: a naturally occurring tolllike receptor 2 agonist that is shed into serum and has synergy with lipopolysaccharide. J. Infect. Dis. 191:939-948. http://dx.doi.org/10.1086/427815. (Pubitemid 40349810)
61. Asai Y, Makimura Y, Ogawa T. 2007. Toll-like receptor 2-mediated dendritic cell activation by a Porphyromonas gingivalis synthetic lipopeptide. J. Med. Microbiol. 56:459-465. http://dx.doi.org/10.1099/jmm.0.46991-0. (Pubitemid 46626561)
62. Shim HK, Kim JY, Kim MJ, Sim HS, Park DW, Sohn JW, Kim MJ. 2009. Legionella lipoprotein activates toll-like receptor 2 and induces cytokine production and expression of costimulatory molecules in peritoneal macrophages. Exp. Mol. Med. 41:687-694. http://dx.doi.org/10.3858/emm.2009.41.10.075.
63. Kirschning CJ, Schumann RR. 2002. TLR2: cellular sensor for microbial and endogenous molecular patterns. Curr. Top. Microbiol. Immunol. 270:121-144. (Pubitemid 35448157)
64. van Eden W, van der Zee R, Prakken B. 2005. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat. Rev. Immunol. 5:318-330. http://dx.doi.org/10.1038/nri1593. (Pubitemid 40516157)
65. Tsan MF, Gao B. 2009. Heat shock proteins and immune system. J. Leukoc. Biol. 85:905-910. http://dx.doi.org/10.1189/jlb.0109005.
66. Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H, Leunissen JA, Heemskerk MH, Falkenburg JH, van Veelen PA. 2013. The human leukocyte antigen-presented ligandome of B lymphocytes. Mol. Cell. Proteomics 12:1829-1843. http://dx.doi.org/10.1074/mcp.M112.024810.
67. Stefanelli P, Fazio C, Fedele G, Spensieri F, Ausiello CM, Mastrantonio P. 2009. A natural pertactin deficient strain of Bordetella pertussis shows improved entry in human monocyte-derived dendritic cells. New Microbiol. 32:159-166.
68. Kedl RM, Rees WA, Hildeman DA, Schaefer B, Mitchell T, Kappler J, Marrack P. 2000. T cells compete for access to antigen-bearing antigenpresenting cells. J. Exp. Med. 192:1105-1113. http://dx.doi.org/10.1084/jem.192.8.1105.
69. Mobberley-Schuman PS, Weiss AA. 2005. Influence of CR3 (CD11b/ CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils. Infect. Immun. 73:7317-7323. http://dx.doi.org/10.1128/IAI.73.11.7317-7323.2005. (Pubitemid 41587632)
70. Mahon BP, Mills KH. 1999. Interferon-gamma mediated immune effector mechanisms against Bordetella pertussis. Immunol. Lett. 68:213-217. http://dx.doi.org/10.1016/S0165-2478(99)00070-X. (Pubitemid 29301879)
71. Torre D, Ferrario G, Bonetta G, Perversi L, Tambini R, Speranza F. 1994. Effects of recombinant human gamma interferon on intracellular survival of Bordetella pertussis in human phagocytic cells. FEMS Immunol. Med. Microbiol. 9:183-188. http://dx.doi.org/10.1111/j.1574-695X.1994.tb00492.x. (Pubitemid 24294324)